{"title": "Eficacia y seguridad de cuatro COVID-19 vacunas para prevenir la infecci\u00f3n por SARS-CoV-2: una revisi\u00f3n r\u00e1pida", "author": "Lina Sof\u00eda Mor\u00f3n-Duarte; Kelly Roc\u00edo Chac\u00f3n; Mar\u00eda Paula Guti\u00e9rrez; Ilich Herbert De La Hoz; Nancy Yomayusa", "url": null, "hostname": null, "description": "Introduction: Since the emergence of the SARS-CoV-2, there have been efforts to develop vaccines to control the COVID-19 pandemic.Objective: The present study assessed the efficacy and safety of the BNT162b2, mRNA-1273, ChAdOx1/AZD1222 and Gam-COVID-Vac rAd26-S/rAd5-S vaccines against theSARS-CoV-2.Materials and methods: We searched PubMed/MEDLINE, Google Scholar, Cochrane, and the WHO International Clinical Trials Registry Platform on March 15, 2021. The searchterms used were: \"vaccine\" OR \"vaccination\" AND \"covid19\" OR \"coronavirus\" OR \"sarscov2\" AND \"bnt162b2\" OR \"chadox1-S\" OR \"azd1222\" OR \"sputnik\" OR \"Gam-COVID-Vac\" OR\"mrna\" OR \"mRNA-1273\" . We measured the risk of bias of the studies and the quality of the evidence using GRADE profiles. A qualitative and quantitative analysis of the results of clinical trials is presented.Results: Of the 74 identified studies, 4 were finally included in this review. The efficacies of the BNT162b2, mRNA-1273, ChAdOx1/AZD1222 and Gam-COVID-VacrAd26-S/rAd5-S vaccines against symptomatic COVID-19 were 95,0% (CI95% 90,3-97,6), 94,1% (CI95% 89,3-96,8), 66,7% (CI95% 57,4-74,0), and 91,1% (CI95% 83,8-95,1), respectively. There was moderate certainty of the evidence due to serious indirectness, when we measured the risk of bias of the studies and the quality of the evidence using GRADE profile. The safety profiles were acceptable, and data on serious adverse events (summary RR=0,93; CI95% 0,77-1,12; p=0,16) and deaths from all causes (summary RR=0,70; CI95% 0,33-1,50; p=0,90) showed no significant differences.Conclusion: The results of this review support the level of evidence for the efficacy and safety of the COVID-19 vaccines analysed.", "sitename": "Biom\u00e9dica", "date": "2022-10-31", "cleaned_text": "Eficacia y seguridad de cuatro COVID-19 vacunas para prevenir la infecci\u00f3n por SARS-CoV-2: una revisi\u00f3n r\u00e1pida Resumen Introducci\u00f3n. Desde que surgi\u00f3 el virus SARS-CoV-2, se han realizado esfuerzos para desarrollar vacunas para controlar la pandemia por COVID-19. Objetivo. Evaluar los datos de la eficacia y seguridad de las vacunas BNT162b2, mRNA-1273, ChAdOx1/AZD1222 y Gam-COVID-Vac rAd26-S/rAd5-S contra el SARS-CoV-2. m\u00e9todos. Se realizaron b\u00fasquedas en PubMed/MEDLINE, Google Scholar, Cochrane y la Plataforma de Registro Internacional de Ensayos Cl\u00ednicos de la OMS el 15 de marzo de 2021. Los t\u00e9rminos usados fueron: \"vaccine\" OR \"vaccination\" OR \"Gam-COVID-Vac\" OR \"mrna\" OR \"mRNA-1273\". Se midi\u00f3 el riesgo de sesgo de los estudios y la calidad de la informaci\u00f3n por medio de los perfiles GRADE. Se presenta un an\u00e1lisis cualitativo y cuantitativo de los resultados de los estudios cl\u00ednicos. Resultados. Se identificaron 74 estudios y se incluyeron 4 en la revisi\u00f3n. La eficacia de las vacunas BNT162b2, mRNA-1273, ChAdOx1/AZD1222 y Gam-COVID-VacrAd26-S/rAd5-S contra (IC95% 83,8-95,1), respectivamente, y hubo una certeza moderada de la informaci\u00f3n debido a la falta de evidencia directa. Los perfiles de seguridad fueron aceptables, y los eventos adversos graves (RR resumido=0,93; IC95% 0,77-1,12; p=0,16) y muerte por todas las causas (RR resumido=0,70; IC95% 0,33-1,50; p=0,90) no mostraron diferencias significativas. Conclusi\u00f3n. Los resultados de esta revisi\u00f3n respaldan el nivel de evidencia de la eficacia y seguridad de las vacunas COVID-19 que fueron analizadas. Descargas Referencias bibliogr\u00e1ficas Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579:265-69. Levin Analysis of the potential impact of durability, timing, and transmission EClinicalMedicine. COVID-19 Vaccine, Emergency Use Authorization (EUA) of the Moderna covid-19 vaccine to prevent coronavirus 2019 (COVID-19). I, Hoffmann TC, Mulrow CD, et al. The PRISMA AD, et al. The Cochrane Collaboration's tool J, Gurtman A, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N et al. cell a a Lockhart S, et al. Phase I/II study of COVID-19 RNA vaccine S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: Gilbride immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost adults [https://doi.org/10.1016/S0140-6736(20)32466-1](https://doi.org/10.1016/S0140-6736(20)32466-1) Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, et al. Phase 1-2 Trial of a SARSCoV-2 recombinant spike N Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. PM, Aley PK, et the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Voysey timing of AI, Zubkova OV, Dzharullaeva AS, et al. Safety and rAd5 vector-based heterologous in Lancet. Disease Control and Prevention. Science Brief: Background rationale and evidence for public health Accessed: April 22, Accessed: May 10, issues it's emergency use validation for a COVID-19 vaccine and emphasizes need reports what does that Johnson's Janssen COVID-19 vaccine and safety. Available [https://www.fda.gov/news-events/pressannouncements/fda-issues-emergency-use-authorization-third-covid-19-vaccine](https://www.fda.gov/news-events/pressannouncements/fda-issues-emergency-use-authorization-third-covid-19-vaccine) Grant MJ, Booth A. A typology of reviews: An analysis of 14 review types and associated methodologies. Health Info Libr M, Ivory J, et al. A scoping review of rapid review methods. BMC Med. 2015;13:224. [https://doi.org/10.1186/s12916-015-0465-6](https://doi.org/10.1186/s12916-015-0465-6) Alberta Health Services. COVID-19 Scientific first set of guidelines on how fully vaccinated people can visit Accessed: May 10, 2021. Available at: [https://www.cdc.gov/media/releases/2021/p0308-vaccinated-guidelines.html](https://www.cdc.gov/media/releases/2021/p0308-vaccinated-guidelines.html) Derechos de autor 2022 Biom\u00e9dica Esta obra est\u00e1 bajo una licencia internacional [Creative Commons Atribuci\u00f3n 4.0](https://creativecommons.org/licenses/by/4.0/). systematic review of maternal and neonatal outcomes, 2023. "}